CROI 2026: HIV Comorbidities

Scritto il 13/05/2026
da Sudipa Sarkar

Top Antivir Med. 2026 Apr;34(2):486-493.

ABSTRACT

Aging-related comorbid conditions have major effects on the health, quality of life, and survival of people with HIV (PWH). The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) featured a number of studies about various comorbid diseases in PWH. Cardiovascular diseases and hypertension were important topics at CROI, with ancillary analyses from the REPRIEVE (Pitavastatin to Prevent Cardiovascular Disease in HIV Infection) trial and studies from lower- and middle-income countries. Metabolic dysfunction-associated fatty liver disease was highlighted in a themed discussion and studies on glucagon-like protein-1 receptor agonists in PWH and antiretroviral-related weight gain were featured prominently in other sessions. Research focusing on aging in PWH was presented, including numerous studies examining the effects of exercise and physical activity and important studies documenting the high prevalence of osteoporosis and frailty in PWH in sub-Saharan Africa. This review focuses on the abstracts presented at CROI 2026 in these areas, highlighting those with the most clinical impact.

PMID:42127259